Acquisition to access global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure loweringAstrazeneca PLC • January 9th, 2023 • Pharmaceutical preparations
AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
